Ask AI

Advances in Personalized TKI Therapy for CP-CML: Nursing Considerations to Enhance Patient Education, Tolerability, and Adherence

Video
This activity is available for 0.75 CME/CE credit(s).

Released: September 09, 2026

Expiration: March 08, 2027

See Activity Collection

Watch this on-demand webcast to explore the latest evidence and best practices for optimizing TKI therapy in chronic phase chronic myeloid leukemia (CP-CML), including individualized treatment selection and sequencing, molecular monitoring, and shared decision-making. Viewers will also examine practical strategies to improve treatment adherence and persistence and proactively identify and manage TKI-related adverse events.

Advances in TKIs for CP CML

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many people with CML do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

The ASC4FIRST trial uniquely focused on comparison of asciminib with investigator-selected, second-generation TKIs for newly diagnosed patients with CP-CML that was Philadelphia chromosome positive.

What were the most recent findings from the 144-wk results of this trial?

4.

A 49-yr-old woman presents with fatigue, night sweats, and splenic discomfort. Her labs are WBC 180,000/µL, platelets 700,000/µL, and blasts 1%. She also has an intermediate Sokal risk score and wants a future pregnancy, so she asks about long-term therapy implications. She is started on 100 mg dasatinib as initial therapy.

The patient returns to the clinic after 2 wk reporting nausea, diarrhea, fatigue, and lower extremity swelling.

What is your next treatment decision?

5.

Among the newly diagnosed patients you are currently caring for with CP-CML, who is likely at the highest risk for suboptimal adherence/ persistence to their TKI therapy?